MENU
+Compare
MYGN
Stock ticker: NASDAQ
AS OF
Jul 22, 04:59 PM (EDT)
Price
$4.60
Change
+$0.15 (+3.37%)
Capitalization
1.93B

MYGN Myriad Genetics Forecast, Technical & Fundamental Analysis

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease... Show more

Industry: #Biotechnology
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MYGN with price predictions
Jul 21, 2025

MYGN's RSI Indicator remains in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on July 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

MYGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 193 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MYGN as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MYGN turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

MYGN moved below its 50-day moving average on July 17, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.460) is normal, around the industry mean (24.694). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.357) is also within normal values, averaging (43.458).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MYGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MYGN is expected to report earnings to fall 72.67% to 0 cents per share on July 31

Myriad Genetics MYGN Stock Earnings Reports
Q2'25
Est.
$-0.01
Q1'25
Beat
by $0.03
Q4'24
Est.
$0.03
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.06
The last earnings report on May 06 showed earnings per share of -2 cents, beating the estimate of -5 cents. With 528.38K shares outstanding, the current market capitalization sits at 1.93B.
A.I. Advisor
published General Information

General Information

a developer of therapeutic and predictive medicine products

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
320 Wakara Way
Phone
+1 801 584-3600
Employees
2700
Web
https://www.myriad.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGLRX17.410.13
+0.75%
Putnam Focused International Equity R
IRVIX25.210.04
+0.16%
Voya Russell Large Cap Value Idx Port I
TIOPX16.420.01
+0.06%
Nuveen International Opps Prem
ERASX41.88-0.24
-0.57%
Eaton Vance Atlanta Capital SMID-Cap R6
WALSX12.74-0.12
-0.93%
Wasatch Long/Short Alpha Investor

MYGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-0.45%
WAT - MYGN
39%
Loosely correlated
-1.97%
GMED - MYGN
37%
Loosely correlated
-7.90%
EMBC - MYGN
33%
Poorly correlated
+5.21%
VCYT - MYGN
31%
Poorly correlated
-2.04%
AORT - MYGN
31%
Poorly correlated
+0.49%
More